Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2012

View Archived Issues

Leo Pharma prepares novel CaS receptor agonists

New lysophospholipid receptor modulators designed by Allergan

New safety data from SMART trials disclosed at ongoing conference

First clinical data reported on new whole-cell cancer vaccine

Significance of LMTK3 SNP explored in Japanese patients with gastric adenocarcinoma

Exelixis presents novel protein kinase inhibitors

Astex Pharmaceuticals patents new FGFR inhibitors

Novel FFA1 receptor agonists disclosed by Boehringer Ingelheim

Amgen divulges new agents for cognition disorders

Extended-release tablet has encouraging effects in patients with depression

Ablynx reports on phase II extension study of ozoralizumab

Lexicon discloses phase IIb data on LX-4211

MAP Pharmaceuticals updates on Levadex NDA

FDA issues complete response letter for Eliquis NDA

Peregrine completes recruitment in bavituximab trial

Milestone achieved in phase IIb tamibarotene study

New phase IIb study investigates RP-103 for NASH

CHMP recommends approval of Afinitor for new indication

Baxter immunoglobulin is the first to be approved in U.S. for MMN

Phase III iferanserin study does not meet endpoints

Neuralstem provides update on phase I trial in major depressive disorder

Novel candidate therapies for schizophrenia developed

European CHMP issues opinion on Humira for severe axial spondyloarthritis

Chugai files for Japanese approval of EGFR inhibitor as first-line therapy for NSCLC

Ongoing phase III rifampicin trial evaluates safety and efficacy in MSA

Rienso obtains E.U. approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...